OncView™ Podcast: NCCN Guideline Updates in HR+ Breast Cancer: Focus on Extended Adjuvant Therapy
This special episode of “Oncology Peer Review On-The-Go” features Lee Schwartzberg, MD, FACP discussing treatment patterns in HR-positive breast cancer with.
As part of its OncView™ video series, CancerNetwork® spoke with Lee Schwartzberg, MD, FACP, of the West Cancer Center and Research Institute in Germantown, Tennessee, about updates to the National Comprehensive Cancer Network (NCCN) guidelines regarding hormone receptor (HR)–positive breast cancer.
In the video series, Lee Schwartzberg, MD, FACP, discussed the following:
- Extended Adjuvant Therapy for HR+ Breast Cancer
- Molecular Biomarkers for HR+ Breast Cancer
- Role of Genomic Testing in HR Positive Breast Cancer
- Appropriateness for Genomic Testing in HR+ Breast Cancer
- Integration of Genomic Testing into NCCN Guidelines
- Current Recommendations for Genomic Testing in HR+ Breast Cancer
- Treatment Limitations in HR+ Breast Cancer
To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
